San Diego, October 2, 2024 – EpicentRx today announce its lead small molecule, RRx-001 (nibrozetone), is the subject of an oral nanosymposium session in amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) at the 2024 Society for Neuroscience (SfN) during...
Press Releases
RRx-001 To Be Featured at the 2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
San Diego, Sept.30, 2024 – EpicentRx, a clinical stage biopharmaceutical company with strong momentum and big plans, will present compelling preclinical data on lead small molecule, RRx-001 (nibrozetone), in Parkinson’s Disease (PD) at the 2024 International Congress...
EpicentRx Receives Highly Competitive US Department of Defense (DoD) Translational Award to Develop RRx-001 as a Neuroprotective Medical Countermeasure
The highly competitive award from the CDMRP Toxic Exposures Research Program will fund the development of EpicentRx’s small molecule, RRx-001 (nibrozetone), as a neuroprotective agent and medical countermeasure against neurotoxic chemical exposures. TORREY PINES, CA,...
EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
Data affirm positive immune effects of AdAPT-001 plus a checkpoint inhibitor in sarcomas and triple negative breast cancer with established checkpoint-inhibitor resistance The paucity of immune related adverse events suggests that AdAPT-001 may protect against them...
EpicentRx to Present Positive Phase 2a Clinical Data with its AdAPT-001 TGF-β Trap Program in Checkpoint Inhibitor Resistant Patients at the 2024 AACR Meeting
Compelling clinical data demonstrate that AdAPT-001, which delivers a TGF-β trap to tumors, reverses established resistance to checkpoint inhibitors and makes checkpoint inhibitors more active SAN DIEGO, April 2, 2024 /PRNewswire/ -- EpicentRx, Inc, a clinical-stage...
EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson’s Disease and ALS/MND at Neuroscience 2023
TORREY PINES, Calif., Nov. 6, 2023 /PRNewswire/ -- EpicentRx, Inc. ("EpicentRx"), a clinical-stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, has been selected for oral and poster presentations at the...
United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee Recognizes New Therapeutic Class by Granting “nibrozetone” as New Generic Name for EpicentRx’s Lead Small Molecule NLRP3 Inhibitor, RRx-001
New USAN name, a shortening of its chemical name, signifies a novel therapeutic class Novel generic name highlights the anti-inflammatory, anticancer, and antioxidant properties of RRx-001 and its potential to address several diverse unmet therapeutic needs TORREY...
EpicentRx Presents Updates on its Oncology Clinical Development Programs at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Company details follow-on Phase 2b study design in head and neck cancer for its lead small molecule candidate, RRx-001 Company also presented positive first-in-human data from its TGF-β trap vector, AdAPT-001 TORREY PINES, Calif., June 2, 2023 /PRNewswire/ --...
EpicentRx Receives Fast Track Designation from the U.S. FDA for Lead Asset, RRx-001, to Prevent/Attenuate Chemotherapy and Radiation Treatment Induced Severe Oral Mucositis
FDA also accepts company's Investigational New Drug (IND) application to initiate a follow-on phase 2b clinical trial, called KEVLARx TORREY PINES, CA, March 29, 2023 — EpicentRx, Inc. (“EpicentRx”), announced today that the U.S. Food and Drug Administration (FDA)...
EpicentRx To Present at International Symposium on the Neuroprotective Effects of RRx-001 in Alzheimer’s and Parkinson’s diseases in Multiple Disease Models
TORREY PINES, Calif., March 28, 2023 -- EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company, has been selected for a symposium presentation at AD/PD 2023, an International Conference on Alzheimer’s & Parkinson’s Diseases taking...
Review of the NLRP3 Inflammasome Inhibitor RRx-001 Published in the Prestigious Scientific Journal, Drugs
RRx-001 is a small molecule direct NLRP3 inflammasome inhibitor with activity in cancer, neurodegeneration, and other inflammatory conditions RRx-001 is the most advanced direct NLRP3 inflammasome inhibitor in clinical development, having been evaluated in over 300...
Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo® [nivolumab] in Traditionally Checkpoint Inhibitor Non-Responsive Tumors
The combination of RRx-001 + Opdivo was well tolerated PRIMETIME was a small, duration-limited pilot study with an encouraging but preliminary anticancer signal in cold, non-immunogenic tumors TORREY PINES, Calif., March 15, 2023 /PRNewswire/ -- EpicentRx, a leading...
EpicentRx Presents Poster on the Nephroprotective Effects of RRx-001 in Patients with Solid Tumors that Receive Cisplatin/Etoposide at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
TORREY PINES, Calif., February 15, 2023 -- EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced that it has been selected for a poster...
EpicentRx Announces Presentation for Phase 2 Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 vs. regorafenib in Third/Fourth Line Colorectal Cancer at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Torrey Pines, Calif., January 20, 2023 - EpicentRx, Inc, a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced data from a Phase 2 randomized clinical trial of...
EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers
Results from PREVLAR trial Demonstrate RRx-001 protects against severe oral mucositis or blistering from radiation in first line head and neck cancer Study published in International Journal of Radiation Oncology, Biology and Physics, also known as The Red Journal...
RRx-001 + Irinotecan Significantly Improved Progression Free Survival (PFS) Versus Regorafenib in the Randomized Phase 2 ROCKET Trial in Advanced Colorectal Cancer
Results from the ROCKET trial, published in the journal Clinical Colorectal Cancer, demonstrate the potential chemoprotective effects of RRx-001 San Diego, Calif., Dec. 14, 2022 - EpicentRx Inc. (“EpicentRx”), a leading-edge, clinical stage biopharmaceutical company...
EpicentRx Announces Patent Issued for Radiation Protection with RRx-001 in Combination Regimens
Dual anti-cancer and radio/chemoprotective agent reduces toxicity from radiation exposure Torrey Pines, Calif., December 6, 2022 - EpicentRx Inc. (“EpicentRx”), a leading-edge, clinical stage biopharmaceutical company that uses groundbreaking science to treat cancer...
EpicentRx Awarded Funding from FightMND to Evaluate Therapeutic Potential of RRx-001 in Motor Neuron Disease (aka ALS)
The funding will support study of lead small molecule inflammasome inhibitor in MND, also known as amyotrophic lateral sclerosis (ALS) Torrey Pines, Calif. and Queensland, Australia, Nov. 29, 2022 /PRNewswire/ - EpicentRx Inc. ("EpicentRx"), a late-stage...
EpicentRx Announces Presentations Focusing on RRx-001 Inhibition of the NLRP3 Inflammasome at Two Upcoming Scientific Conferences
Presentations at Neuroscience 2022 and the 4th Inflammasome Therapeutics Summit will highlight the potential for RRx-001 to prevent and treat a broad range of chronic diseases Torrey Pines, Calif., November 10, 2022 – EpicentRx, a late clinical stage biopharmaceutical...
EpicentRx Announces First Patient Dosed in China for the Phase 3 REPLATINUM Global Study with RRx-001 in Third Line and Beyond Extensive Stage Small Cell Lung Cancer (SCLC)
License partner SciClone Pharmaceuticals oversees trial in China. Phase 3 REPLATINUM multicenter clinical trial with over 50 sites in the U.S. and China is underway Torrey Pines, Calif., Oct. 6, 2022 /PRNewswire/ - EpicentRx, a late clinical stage biopharmaceutical...
EpicentRx Publishes Commentary in International Journal of Infectious Disease (IJID) on Need for a “Universal” Coronavirus Vaccine to be More Effective Against Novel Viral Variants
Commentary points to need for a vaccine based on nucleocapsid vs. spike protein to make vaccine less vulnerable to mutation and provide stronger immunity to novel viral variants Company’s development of a nucleocapsid vaccine, a recombinant replication-competent...
New industry partnership to accelerate development of Parkinson’s disease treatments
BRISBANE, AUSTRALIA, July 12, 2022 – University of Queensland researchers will partner with American biopharmaceutical company EpicentRx Inc. to evaluate new treatments for Parkinson’s disease (PD), speeding up development of potential new therapies. UQ and EpicentRx...
EpicentRx Awarded Grant from The Michael J. Fox Foundation to Evaluate Therapeutic Potential of RRx-001 in Parkinson’s Disease
The $500,000 USD grant will support study of EpicentRx’s lead small molecule inflammasome inhibitor TORREY PINES, Calif., July 12, 2022 -- EpicentRx Inc. (“EpicentRx”), a late-stage biopharmaceutical company developing platforms that treat and target multiple...
EpicentRx Announces Poster Presentation for Phase 2 Randomized Clinical Trial with RRx-001 as an Anti-Mucositis Agent in Locally Advanced Head and Neck Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
TORREY PINES, Calif., June 1, 2022 -- EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of developing oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that...
EpicentRx Announces Oral and Poster Presentations at the 2022 American Thoracic Society (ATS) Respiratory Innovation Summit
TORREY PINES, Calif., May 10, 2022 -- EpicentRx, Inc., a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that it has been...
EpicentRx “BETA-PRIME” Phase 1 Study Progresses After Demonstrating Good Safety and Tolerability
Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer TORREY PINES, Calif., April 21, 2022 -- EpicentRx Inc., a leading-edge immunotherapy company using...
EpicentRx and Texas Children’s Cancer Center Announce the Initiation of a Phase 1 Clinical Trial with RRx-001 for Pediatric CNS Tumors
TORREY PINES, Calif., Feb. 23, 2022 – EpicentRx, Inc., a clinical stage drug and device company, in collaboration with the Texas Children's Cancer Center in Houston, today announced the start of a Phase 1 study to examine the safety and benefit of its lead small...
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
Collaboration builds on recent data presented by Actinium at SITC demonstrating enhanced activity of targeted radiotherapies in combination with the anti-CD47 targeting antibody magrolimab in blood cancer and solid tumor models Collaboration to explore Actinium’s...
EpicentRx Publishes Proof-of-Concept Research on AdAPT-001
Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap La Jolla, Calif., Dec. 8, 2021 - EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...
EpicentRx Granted New Composition of Matter Patent for Its TGF-ß Trap Fusion Protein
La Jolla, Calif., Nov. 22, 2021 - EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and...
EpicentRx Announces Publication of Phase 1 Trial Results for the Anti-Cancer Agent, RRx-001, in Lancet Oncology
MOUNTAIN VIEW, Calif., August 19, 2015 -- EpicentRx, Inc., a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of potent, novel anti-cancer agents, announced today the publication of positive results...
First Patient Treated With Next-Generation Immunotherapy at UC Cincinnati
EpicentRx Announces Completion of First Cohort in Phase 1 “BETA PRIME” Trial with AdAPT-001
Cancer-targeting adenovirus enhanced with a TGFβ Trap well tolerated in patients with advanced cancer Torrey Pines, Calif., Sept. 29, 2021- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today announced...
EpicentRx, Inc. in an Expansive Growth Phase
Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...
EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China
SciClone granted exclusive license to co-develop and commercialize RRx-001 upon approval in the Greater China Region LA JOLLA, Calif., July 1, 2020 -- EpicentRx Inc. ("EpicentRx"), a San Diego-based clinical cancer immunotherapy company and SciClone Pharmaceuticals...
EpicentRx Appoints Life Sciences Investment Banking Veteran, Dr. Franck Brinkhaus, as President and Chief Financial Officer
TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...
EpicentRx Appoints Oncologist Tony Reid, M.D., Ph.D., as Chief Executive Officer (CEO)
TORREY PINES, Calif., May 29, 2020 -- EpicentRx, a next-generation clinical immuno-oncology company, today announced the appointment of physician, scientist and businessman Tony Reid, M.D., Ph.D., as the company's chief executive officer. Dr. Reid who is a co-founder...
EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance
EpicentRx’s lead program is the first-in-class small molecule CD47 antagonist RRx-001 in Phase 3 for small cell lung cancer Enrollment of Phase I trial for adenovirus program AIM-001 expected to begin this year Close of recent $35M series D will advance AIM-001 and...
EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck Brinkhaus as Chief Financial Officer
TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...
EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma
RRx-001 led to an overall survival of 21.9 months and progression-free survival of 13 months Data presented at the Society for Neuro-Oncology annual meeting LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune...
EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform
Series D Funded by an undisclosed source from Europe Total capital raised by EpicentRx approximately $77 million LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with...
EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer
LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has dosed the first patient in the Phase 3 REPLATINUM trial evaluating...
EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)
LA JOLLA, Calif., June 25, 2019 -- EpicentRx Inc., a clinical-stage immuno-oncology company with two platforms developed to prime and activate both innate and adaptive anticancer responses, today announced the publication of positive results from its Phase 2 clinical...
EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines
SAN DIEGO, May 2, 2018 -- EpicentRx, a San Diego biotechnology company developing a next-generation immunotherapy platform of viruses that infect and kill cancer cells for the treatment of several tumor types, has developed the first ever series of oncolytic viruses...